186 related articles for article (PubMed ID: 29453962)
21. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer.
Zhang L; Wang H; Dong X
J Bras Pneumol; 2018; 44(1):18-23. PubMed ID: 29538538
[TBL] [Abstract][Full Text] [Related]
23. Complement factor H autoantibodies are associated with early stage NSCLC.
Amornsiripanitch N; Hong S; Campa MJ; Frank MM; Gottlin EB; Patz EF
Clin Cancer Res; 2010 Jun; 16(12):3226-31. PubMed ID: 20515868
[TBL] [Abstract][Full Text] [Related]
24. Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.
Li M; Zhang Q; Wu L; Jia C; Shi F; Li S; Peng A; Zhang G; Song X; Wang C
Oncol Rep; 2014 Apr; 31(4):1961-7. PubMed ID: 24549225
[TBL] [Abstract][Full Text] [Related]
25. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
[TBL] [Abstract][Full Text] [Related]
26. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
28. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
29. High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer.
Lu J; Wang Y; Yan M; Feng P; Yuan L; Cai Y; Xia X; Liu M; Luo J; Li L
Oncotarget; 2016 Jul; 7(27):41758-41766. PubMed ID: 27248178
[TBL] [Abstract][Full Text] [Related]
30. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer.
Farlow EC; Patel K; Basu S; Lee BS; Kim AW; Coon JS; Faber LP; Bonomi P; Liptay MJ; Borgia JA
Clin Cancer Res; 2010 Jul; 16(13):3452-62. PubMed ID: 20570928
[TBL] [Abstract][Full Text] [Related]
31. Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer.
Yao X; Jiang H; Zhang C; Wang H; Yang L; Yu Y; Yu J; Shi B; Shen Z; Gao H; Chen Z; Tian S; Lu S; Li Z; Gu J
Biomarkers; 2010 Mar; 15(2):128-34. PubMed ID: 19839718
[TBL] [Abstract][Full Text] [Related]
32. Serum anti-CCNY autoantibody is an independent prognosis indicator for postoperative patients with early-stage nonsmall-cell lung carcinoma.
Ma L; Yue W; Teng Y; Zhang L; Gu M; Wang Y
Dis Markers; 2013; 35(5):317-25. PubMed ID: 24167380
[TBL] [Abstract][Full Text] [Related]
33. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
34. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.
Shih NY; Lai HL; Chang GC; Lin HC; Wu YC; Liu JM; Liu KJ; Tseng SW
Jpn J Clin Oncol; 2010 Jul; 40(7):663-9. PubMed ID: 20395242
[TBL] [Abstract][Full Text] [Related]
35. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer.
Xu C; Li L; Wang W; Zhang Q; Zhang X; Yang R
J Cell Mol Med; 2021 Mar; 25(6):3169-3172. PubMed ID: 33605059
[TBL] [Abstract][Full Text] [Related]
36. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
37. Early detection of NSCLC with scFv selected against IgM autoantibody.
Pedchenko T; Mernaugh R; Parekh D; Li M; Massion PP
PLoS One; 2013; 8(4):e60934. PubMed ID: 23585862
[TBL] [Abstract][Full Text] [Related]
38. Rethinking Autoantibody Signature Panels for Cancer Diagnosis.
Campa MJ; Gottlin EB; Herndon JE; Patz EF
J Thorac Oncol; 2017 Jun; 12(6):1011-1014. PubMed ID: 28126538
[TBL] [Abstract][Full Text] [Related]
39. Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.
Zhang K; Chen L; Deng H; Zou Y; Liu J; Shi H; Xu B; Lu M; Li C; Jiang J; Wang Z
Int J Clin Exp Pathol; 2015; 8(1):629-35. PubMed ID: 25755755
[TBL] [Abstract][Full Text] [Related]
40. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
